Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 1.03
EGLT's Cash-to-Debt is ranked lower than
80% of the 864 Companies
in the Global Biotechnology industry.

( Industry Median: 53.59 vs. EGLT: 1.03 )
Ranked among companies with meaningful Cash-to-Debt only.
EGLT' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.18  Med: 1.82 Max: No Debt
Current: 1.03
Equity-to-Asset 0.05
EGLT's Equity-to-Asset is ranked lower than
90% of the 635 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. EGLT: 0.05 )
Ranked among companies with meaningful Equity-to-Asset only.
EGLT' s Equity-to-Asset Range Over the Past 10 Years
Min: -3.39  Med: 0.05 Max: 0.73
Current: 0.05
-3.39
0.73
Piotroski F-Score: 2
Altman Z-Score: -3.79
Beneish M-Score: 0.61
WACC vs ROIC
4.17%
-2046.38%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -477.62
EGLT's Operating Margin % is ranked lower than
70% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: -97.80 vs. EGLT: -477.62 )
Ranked among companies with meaningful Operating Margin % only.
EGLT' s Operating Margin % Range Over the Past 10 Years
Min: -1934.17  Med: -477.62 Max: -228.72
Current: -477.62
-1934.17
-228.72
Net Margin % -534.26
EGLT's Net Margin % is ranked lower than
72% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: -83.37 vs. EGLT: -534.26 )
Ranked among companies with meaningful Net Margin % only.
EGLT' s Net Margin % Range Over the Past 10 Years
Min: -2250.73  Med: -534.26 Max: -253.76
Current: -534.26
-2250.73
-253.76
ROE % -186.26
EGLT's ROE % is ranked lower than
88% of the 773 Companies
in the Global Biotechnology industry.

( Industry Median: -39.29 vs. EGLT: -186.26 )
Ranked among companies with meaningful ROE % only.
EGLT' s ROE % Range Over the Past 10 Years
Min: -444.79  Med: -191.72 Max: -86.8
Current: -186.26
-444.79
-86.8
ROA % -63.81
EGLT's ROA % is ranked lower than
73% of the 870 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. EGLT: -63.81 )
Ranked among companies with meaningful ROA % only.
EGLT' s ROA % Range Over the Past 10 Years
Min: -307.77  Med: -123.58 Max: -49.73
Current: -63.81
-307.77
-49.73
ROC (Joel Greenblatt) % -702.45
EGLT's ROC (Joel Greenblatt) % is ranked lower than
55% of the 827 Companies
in the Global Biotechnology industry.

( Industry Median: -476.30 vs. EGLT: -702.45 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
EGLT' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1093.04  Med: -822.41 Max: -672.52
Current: -702.45
-1093.04
-672.52
3-Year EBITDA Growth Rate 61.60
EGLT's 3-Year EBITDA Growth Rate is ranked higher than
92% of the 515 Companies
in the Global Biotechnology industry.

( Industry Median: 0.20 vs. EGLT: 61.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
EGLT' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -13.2 Max: 61.6
Current: 61.6
0
61.6
3-Year EPS without NRI Growth Rate -38.20
EGLT's 3-Year EPS without NRI Growth Rate is ranked lower than
84% of the 501 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. EGLT: -38.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
EGLT' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -38.2 Max: -11.1
Current: -38.2
GuruFocus has detected 5 Warning Signs with Egalet Corp $EGLT.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» EGLT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

EGLT Guru Trades in Q2 2015

Jim Simons 36,400 sh (New)
» More
Q3 2015

EGLT Guru Trades in Q3 2015

Jim Simons 31,800 sh (-12.64%)
» More
Q4 2015

EGLT Guru Trades in Q4 2015

Jim Simons 47,300 sh (+48.74%)
» More
Q1 2016

EGLT Guru Trades in Q1 2016

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with EGLT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:CBAY, OTCPK:CTIX, NAS:AGTC, NAS:CTIC, NAS:CDTX, NAS:APEN, NAS:VTL, NAS:PSTI, NAS:VVUS, NAS:ATHX, NAS:ZFGN, NAS:CNAT, NAS:OPHT, NAS:PIRS, NAS:MRTX, NAS:NVIV, NAS:ADVM, NAS:GLYC, NAS:GEMP, OTCPK:PAIOF » details
Traded in other countries:EGP.Germany,
Egalet Corp is a specialty pharmaceutical company. The Company is engaged in developing and planning to commercialize proprietary, abuse-deterrent oral products for the treatment of pain and in other indications.

Egalet is a specialty biopharmaceutical company involved in the development and commercialization of pain treatments. Using its proprietary Guardian Technology, the company developed an extended-release morphine product, ARYMO ER, within the therapeutic area of severe pain management. Moreover, Egalet markets two novel pain products: SPRIX (ketorolac tromethamine) nasal spray, and OXAYDO (oxycodone HCl, USP) tablets for oral use.

Ratios

vs
industry
vs
history
PB Ratio 22.84
EGLT's PB Ratio is ranked lower than
93% of the 1091 Companies
in the Global Biotechnology industry.

( Industry Median: 3.76 vs. EGLT: 22.84 )
Ranked among companies with meaningful PB Ratio only.
EGLT' s PB Ratio Range Over the Past 10 Years
Min: 1.41  Med: 3.37 Max: 41.56
Current: 22.84
1.41
41.56
PS Ratio 6.96
EGLT's PS Ratio is ranked higher than
66% of the 854 Companies
in the Global Biotechnology industry.

( Industry Median: 12.99 vs. EGLT: 6.96 )
Ranked among companies with meaningful PS Ratio only.
EGLT' s PS Ratio Range Over the Past 10 Years
Min: 3.5  Med: 44.71 Max: 670
Current: 6.96
3.5
670
Current Ratio 3.74
EGLT's Current Ratio is ranked lower than
53% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. EGLT: 3.74 )
Ranked among companies with meaningful Current Ratio only.
EGLT' s Current Ratio Range Over the Past 10 Years
Min: 0.17  Med: 3.02 Max: 7.42
Current: 3.74
0.17
7.42
Quick Ratio 3.67
EGLT's Quick Ratio is ranked lower than
51% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. EGLT: 3.67 )
Ranked among companies with meaningful Quick Ratio only.
EGLT' s Quick Ratio Range Over the Past 10 Years
Min: 0.17  Med: 2.98 Max: 7.42
Current: 3.67
0.17
7.42
Days Inventory 177.57
EGLT's Days Inventory is ranked lower than
65% of the 384 Companies
in the Global Biotechnology industry.

( Industry Median: 132.21 vs. EGLT: 177.57 )
Ranked among companies with meaningful Days Inventory only.
EGLT' s Days Inventory Range Over the Past 10 Years
Min: 102.49  Med: 139.43 Max: 177.57
Current: 177.57
102.49
177.57
Days Sales Outstanding 23.84
EGLT's Days Sales Outstanding is ranked higher than
79% of the 535 Companies
in the Global Biotechnology industry.

( Industry Median: 59.11 vs. EGLT: 23.84 )
Ranked among companies with meaningful Days Sales Outstanding only.
EGLT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 4.72  Med: 56.56 Max: 321.28
Current: 23.84
4.72
321.28
Days Payable 238.55
EGLT's Days Payable is ranked higher than
85% of the 353 Companies
in the Global Biotechnology industry.

( Industry Median: 58.37 vs. EGLT: 238.55 )
Ranked among companies with meaningful Days Payable only.
EGLT' s Days Payable Range Over the Past 10 Years
Min: 238.55  Med: 533.1 Max: 827.64
Current: 238.55
238.55
827.64

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -19.80
EGLT's 3-Year Average Share Buyback Ratio is ranked lower than
70% of the 563 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. EGLT: -19.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
EGLT' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -168.8  Med: -19.8 Max: 0
Current: -19.8
-168.8
0

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.16
EGLT's Price-to-Median-PS-Value is ranked higher than
95% of the 750 Companies
in the Global Biotechnology industry.

( Industry Median: 1.02 vs. EGLT: 0.16 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
EGLT' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.15  Med: 0.25 Max: 0.94
Current: 0.16
0.15
0.94
Earnings Yield (Greenblatt) % -68.08
EGLT's Earnings Yield (Greenblatt) % is ranked lower than
95% of the 1273 Companies
in the Global Biotechnology industry.

( Industry Median: -8.24 vs. EGLT: -68.08 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
EGLT' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -2500  Med: 0 Max: 0
Current: -68.08
-2500
0

More Statistics

Revenue (TTM) (Mil) $16.96
EPS (TTM) $ -3.70
Beta0.53
Short Percentage of Float44.70%
52-Week Range $4.34 - 10.00
Shares Outstanding (Mil)25.21

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 39 60 85
EPS ($) -3.05 -2.40 -1.60
EPS without NRI ($) -3.05 -2.40 -1.60
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for EGLT

Headlines

Articles On GuruFocus.com
Wall Street’s Best and Worst Calls of the First Quarter 2015 May 07 2015 

More From Other Websites
IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Egalet... Mar 24 2017
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Egalet... Mar 24 2017
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Has Filed a Complaint to Recover... Mar 24 2017
Blog Coverage Egalet Receives New US and International Patents for Guardian(TM) Technology Mar 24 2017
Egalet Gets 4 New Patents for Guardian Technology Mar 23 2017
Egalet Announces Issuance of New U.S. and International Patents for Guardian™ Technology Mar 23 2017
INVESTOR NOTICE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Egalet... Mar 21 2017
EGLT INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving... Mar 21 2017
Pain Therapeutics’ Remoxy ER Secures FDA Regulatory Guidance (PTIE,EGLT) Mar 21 2017
Nektar Pharma Opioid Drug Shows Promise In Phase 3 Mar 20 2017
Egalet Corp. :EGLT-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017 Mar 20 2017
DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Egalet... Mar 20 2017
SHAREHOLDER NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Egalet... Mar 20 2017
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Egalet... Mar 17 2017
EGALET CORP Financials Mar 17 2017
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Has Filed a Complaint to Recover... Mar 17 2017
Egalet Corp. :EGLT-US: Earnings Analysis: 2016 By the Numbers : March 15, 2017 Mar 15 2017
SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Egalet... Mar 15 2017
How Endo's FDA Committee Vote Affects Egalet Mar 15 2017
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against... Mar 15 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)